Rabies Virus G Protein Epitope Binding Molecule
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current rabies treatments, such as human-derived and equine-derived immunoglobulins, face challenges including inefficient supply, high costs, and potential infections, while monoclonal antibodies have limitations like short half-life and immune response issues, necessitating the development of a human monoclonal antibody with high safety and efficacy for rabies treatment.
Innovation Solution
A rabies-virus-neutralizing binding molecule that targets specific epitopes on the rabies virus G protein, combined with an immunoconjugate and nucleic acid molecule for production and administration, to create a medicinal composition for diagnosis, prevention, and treatment of rabies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If human-derived rabies immunoglobulin (HRIG) is used for passive immunization, then neutralizing efficacy against rabies virus is achieved, but supply efficiency is low, cost is high, and risk of human-derived disease transmission exists
Solution Approach 1:
The patent uses recombinant DNA technology to copy the gene encoding the rabies virus G protein epitope and inserts it into an expression vector, which is then transformed into host cells (insect cells) for mass production. This copying approach enables scalable production of the binding molecule without relying on limited human plasma resources, directly resolving the supply efficiency contradiction while maintaining neutralizing efficacy.
2Productivity
If equine-derived rabies immunoglobulin (ERIG) is used for passive immunization, then supply efficiency and cost-effectiveness are improved, but therapeutic efficiency is low and anaphylaxis risk occurs
Solution Approach 1:
The patent changes the source parameter from equine to human-compatible recombinant production system, and optimizes the binding molecule's affinity parameters through epitope selection. The recombinant binding molecule exhibits high neutralizing activity comparable to or exceeding HRIG, while being produced in insect cells to avoid human plasma contamination risks, thus improving both therapeutic efficiency and safety without compromising supply efficiency.
3Ease of manufacture
If mouse monoclonal antibody is used for rabies treatment, then monoclonal antibody advantages (uniformity, scalability) are achieved, but half-life is short, immune response is absent, and HAMA induction occurs
Solution Approach 1:
The patent uses an insect cell expression system as an intermediary platform to produce the humanized binding molecule. This intermediary system allows for scalable recombinant production like mouse monoclonal antibodies, while the humanized nature of the binding molecule ensures compatibility with human physiology, extending half-life and avoiding HAMA induction that plagues mouse-derived antibodies.
4Adaptability or versatility
If polyclonal antibody (HRIG) is used, then broad neutralizing activity is achieved, but efficacy per unit weight is low due to polyclonal nature
Solution Approach 1:
The patent extracts the specific epitope sequence from the rabies virus G protein and designs a monoclonal binding molecule that targets this specific epitope. This extraction approach concentrates neutralizing activity into a single high-affinity binding molecule, eliminating the dilution effect inherent in polyclonal antibodies and achieving superior efficacy per unit weight while maintaining broad neutralizing activity through epitope conservation across rabies virus strains.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The binding molecule effectively neutralizes the rabies virus, offering high safety, uniform quality, and efficient production, addressing the limitations of existing treatments by providing a therapeutically effective and safe solution for rabies prevention and treatment.
Implementation Method 1
a rabies-virus-neutralizing binding molecule that binds specifically to a rabies virus G protein epitope
Data Source
AI summary
This invention relates to a rabies virus G protein epitope and a rabies-virus-neutralizing binding molecule that binds specifically thereto, wherein different epitope sites of rabies virus G protein are identified and binding molecules that bind thereto and a cocktail thereof can be found to retain neutralizing activity against various rabies viruses.